Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
July 12 2021 - 8:00AM
Business Wire
AditxtScore™ for COVID-19 Now Includes
Virus-Specific Infection Blocking Antibodies that Assess the
Strength of an Individual’s Immune Response to SARS-CoV-2
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation
company with a mission to improve the health of the immune system,
today announced enhancements to its AditxtScore™ for COVID-19. A
multi-dimensional immune response test that tracks multiple
combinations of antibody responses against several different
antigens, AditxtScore for COVID-19 has been enhanced to include a
high-sensitivity neutralizing antibody diagnostic, which makes it
possible to assess the strength of an individual’s immune response
to the SARS-CoV-2 virus.
“Everyone’s immune response is unique to that individual. We
have been studying individual immune responses to COVID-19 and
COVID-19 vaccination, and we are finding that the immediacy,
strength, and duration of antibody responses can vary widely based
on a multitude of variables,” said Amro Albanna, Co-founder and
Chief Executive Officer of Aditxt. “The addition of this new
AditxtScore for COVID-19 captures important data on how effective
an individual’s antibodies are for inactivating the virus. We
believe that as more people become vaccinated or exposed to the
virus, AditxtScore for COVID-19 with neutralizing antibody
diagnostics adds that next level of precision, delivering more
detailed information of the strength of immune response against the
virus.”
AditxtScore for COVID-19, which was first introduced in August
of 2020, differentiates itself from traditional antibody tests by
delivering a detailed view of an individual’s immune response to
multiple antigens associated with the SARS-CoV-2 virus. This
multi-multiplex approach to capturing the full spectrum of
biomarkers associated with SARS-CoV-2 delivers a highly detailed
snapshot of an individual’s immune response in a single test cycle.
With this new enhancement, AditxtScore for COVID-19 now includes
the ability to measure neutralizing antibodies, the subset of
virus-specific antibodies that block infection by interfering with
cell entry of virus particles.
The level of precision in AditxtScore for COVID-19, along with
its ability to measure the neutralizing activity of IgG, IgM and
IgA isotypes, can provide clinicians with the data they need to
understand the strength and quality of each individual’s immune
response to COVID-19, whether through exposure and infection or
vaccination. Furthermore, it allows identification of individuals
who are vulnerable to SARS-CoV-2 infection due to absence of
previous exposure to the virus or vaccines, but possibly more
importantly, due to an inadequate immune response to vaccination or
infection. This information is critical for the millions of
immunocompromised patients who may not develop an adequate immune
response to vaccination or exposure for multiple reasons,
including: immunosuppressive disease, immunosuppressant
medications, anti-cancer medications affecting immune function, or
the presence of long-term chronic disease that has exhausted the
body’s natural immune response capacity.
AditxtScore for COVID-19 is offered through authorized channel
partners. To find an AditxtScore Channel Partner near you, please
visit www.aditxtscore.com. AditxtScore for COVID-19 is available
for use as a CLIA-validated laboratory developed test (LDT). This
test is not for self-diagnosis and is not cleared or approved by
the FDA.
About Aditxt:
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt’s immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt’s immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s intellectual property position; the Company’s ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company’s results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
titled “Risk Factors” in the Company’s most recent Annual Report on
Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210712005125/en/
Media and Investor Relations Contact: Sunny Uberoi Chief
Communications Officer Aditxt ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024